TVRD vs. SNDX, ARDX, RCUS, TLRY, JANX, PHVS, XERS, STOK, EVO, and ZYME
Should you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), Arcus Biosciences (RCUS), Tilray Brands (TLRY), Janux Therapeutics (JANX), Pharvaris (PHVS), Xeris Biopharma (XERS), Stoke Therapeutics (STOK), Evotec (EVO), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry.
Tvardi Therapeutics vs. Its Competitors
Tvardi Therapeutics (NASDAQ:TVRD) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.
Tvardi Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
44.7% of Tvardi Therapeutics shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Syndax Pharmaceuticals has a net margin of -428.48% compared to Tvardi Therapeutics' net margin of -678.79%. Syndax Pharmaceuticals' return on equity of -130.47% beat Tvardi Therapeutics' return on equity.
Tvardi Therapeutics presently has a consensus target price of $64.25, suggesting a potential upside of 62.86%. Syndax Pharmaceuticals has a consensus target price of $39.22, suggesting a potential upside of 153.46%. Given Syndax Pharmaceuticals' higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Tvardi Therapeutics.
In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 2 mentions for Syndax Pharmaceuticals and 1 mentions for Tvardi Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 0.51 beat Tvardi Therapeutics' score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
Tvardi Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals.
Summary
Syndax Pharmaceuticals beats Tvardi Therapeutics on 12 of the 14 factors compared between the two stocks.
Get Tvardi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tvardi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TVRD) was last updated on 10/3/2025 by MarketBeat.com Staff
